Skip to Content

Besivance Approval History

FDA Approved: Yes (First approved May 28, 2009)
Brand name: Besivance
Generic name: besifloxacin
Dosage form: Ophthalmic Suspension
Company: Bausch & Lomb
Treatment for: Conjunctivitis, Bacterial

Besivance (besifloxacin ophthalmic suspension) is a topical quinolone antimicrobial for the treatment of bacterial conjunctivitis, commonly referred to as "pink eye."

Development History and FDA Approval Process for Besivance

DateArticle
May 29, 2009Approval Bausch & Lomb Receives FDA Approval of Besivance, New Topical Ophthalmic Antibacterial for the Treatment of Bacterial Conjunctivitis ('Pink Eye')
Dec  5, 2008FDA Advisory Committee Recommends Approval of Bausch & Lomb Besifloxacin Anti-Infective Eye Drop

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide